- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02923102
Effects of Recoverben® on Recovery After Exhaustive Exercise
Effects of Recoverben® on Recovery After Exhaustive Exercise in Healthy People - a Randomized, Double-blind, Placebo-controlled Study With Parallel Design
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of the study is to investigate a pre and post workout supplementation (15 days) with Recoverben® , a Aloysia citriodora extract on recovery after exhaustive exercise. Effects will be investigated with 400mg Recoverben® and compared to placebo.
Targeted parameter will be determined at the beginning of the study and after supplementation, each. Parameter include maximal strength (MVC), muscle soreness (VAS), pain sensitivity (Algometry) and biomarkers (CK, IL-6, glutathione peroxidase).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Esslingen, Germany, 73728
- BioTeSys GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
- Health volunteers: Subject is in good physical and mental health as established by medical his-tory, physical examination, electrocardiogram, vital signs, results of biochemistry and haematology
- Men and women
- Age ≥ 22 and ≤ 50 years
- BMI: 19-30 kg/m2
- Physically active 1-3 times per week
- Nonsmoker
- Able and willing to follow the study protocol procedures
Exclusion Criteria:
- Relevant history, presence of any medical disorder or chronic intake of medication/dietary supplements (e.g. polyphenols, anti-inflammatory or anti-oxidative drugs or supplements, antihyper-tensive drugs) potentially interfering with this study at screening.
- For this study clinically relevant abnormal laboratory, vital signs or physical findings at screening
- Diabetes or serious cardiovascular diseases
- Change of dietary habits within the 2 weeks prior to screening (for instance start of a diet high in vegetables and fruits (≥ 5 portions per day))
- Diet high in vegetables and fruits ≥ 5 portions per day
- Participants anticipating a change in their lifestyle or physical activity levels during the study.
- Subjects not willing to abstain from intake of analgesic medication (e.g. Aspirin) 24 hours prior to visit 2 until visit 5.
- Subjects with history of drug, alcohol or other substances abuse, or other factors limiting their ability to co-operate during the study.
- Known hypersensitivity to the study preparation or to single ingredients
- Pregnant subject or subject planning to become pregnant during the study; breast-
- Known HIV-infection
- Known acute or chronic hepatitis B and C infection
- Blood donation within 4 weeks prior to visit 1 or during the study.
- Subject involved in any clinical or food study within the preceding month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Aloysia citriodora extract
Dietary Supplement: Aloysia citriodora extract
|
2 capsules with 200mg - daily dosage 400mg
Other Names:
|
PLACEBO_COMPARATOR: Placebo Formulation
Dietary Supplement: Maltodextrin (no active ingredient)
|
2 capsules with 200mg - daily dosage 400mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of muscle soreness (VAS) over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 3h, 24h, 48 h, 96h after stress test)
|
In the current study, pain following eccentric exercise will be assessed by using a 100 mm visual analogue scale after the subjects performing a standardized movement.
|
Chance over time after 10 days of supplementation (pre stress test and 3h, 24h, 48 h, 96h after stress test)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monitoring of related adverse events
Time Frame: During study execution over 15 days
|
Reporting of adverse effects to evaluate tolerability
|
During study execution over 15 days
|
Change of maximal concentric strength/ maximal voluntary contraction (MVC) over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
|
Maximal concentric strength of the M. Quadriceps femoris will be assessed by measuring maximal isometric concentric strength using a dynamometer
|
Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
|
Change of pressure pain (Algometry) over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
|
The threshold for pressure induced pain will be measured using an algometer.
|
Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
|
Change of retrospective pain (Likert scale) over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 24h, 48h, 96h after stress test)
|
Evaluation of the perceived pain retrospectively by using the Likert scale for muscle soreness
|
Chance over time after 10 days of supplementation (pre stress test and 24h, 48h, 96h after stress test)
|
Change of creatine kinase over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
|
Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
|
|
Change of of glutathione peroxidase over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 24h and 48 h after stress test)
|
Chance over time after 10 days of supplementation (pre stress test and 24h and 48 h after stress test)
|
|
Change of interleukin-6 over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
|
Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Claudia Reule, Dr., BioTeSys GmbH
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTS822/14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Aloysia citriodora extract
-
Access Business GroupCompleted
-
University Hospitals Cleveland Medical CenterUnknownAsthma | Allergic Rhinitis | Allergic ConjunctivitisUnited States
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompletedAsthma | Perennial Allergic RhinitisUnited States
-
SeppicCompleted
-
Mahidol UniversityCompleted
-
Unilever R&DCompleted
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingBreast CarcinomaUnited States
-
Activ'insideCIC SANPSY (USR CNRS 3413), Groupe Hospitalier Pellegrin, Bordeaux, FranceCompleted
-
Medical Life Care Planners, LLCNot yet recruitingHair Diseases | Hirsutism
-
Bionorica SECompleted